Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript. The company reported existing debt of INR 5 crores and cash equivalents of INR 5.2 crores as of September 2024. They have indicated expected capex of around INR 3.5 crores for the base business in FY25 and INR 35-40 crores for the HAL venture in FY25. The company seems focused on internal capital allocation and managing working capital efficiently to support growth. No direct commentary on raising additional funds through debt or equity was made during the call.

Any current/future capex/capital investment/strategic investment?

Capex for the base business was INR 1.46 crores in H1 FY25; expected to be around INR 3.5 crores for FY25 and INR 5.5 crores for FY26. HAL venture (IV business) capex expected to be around INR 35-40 crores for FY25. New facility in Pune for infusion project is in pipeline and undergoing various approvals; requiring additional capital and technical hires. Plant upgrades nearly completed at the Bombay facility; Dehradun facility upgrades to begin soon. Potential future expansions in Prague facility targeting EUR 8-10 million revenue with possibility of adding a bigger facility. Discussions ongoi

Future growth expectations in sales/revenue/volumes?

Nutraceutical market is constantly growing globally, presenting strong demand growth potential. Prague JV business expected to stabilize by Q1 FY26, with annual topline of approx. EUR3.5-4 million initially. Medium to long-term potential for Prague facility estimated at EUR8-10 million annually by FY27, with scope for expansion. HAL facility peak revenue potential around INR 105-110 crores with 19% EBITDA margin; capacity utilization expected to reach 95-100% within a few months of operation. Base business sees growth driven by geographic expansion, new product launches (targeting 15-20 launch

Future growth expectations in earnings/operating earnings/profits/EPS?

Nutraceutical market is expected to grow constantly worldwide, supporting uplift in related revenues. Prague facility (JV) projected to stabilize by Q1 FY26 with an annual revenue estimate of EUR3.5-4 million and EBITDA margins of 25%-30%. Medium to long term potential from Prague entity estimated at EUR8-10 million annually post-expansion by FY27. HAL facility expected to reach peak revenue of INR105-110 crores with EBITDA margins around 19%, achieving near full capacity utilization within a few months. The company targets launching 15-20 new products annually to expand product portfolio and

Current/ Expected Orderbook/ Pending Orders?

Sanjivani Paranteral Limited is currently executing a few small orders for its Prague facility and is in discussions with several big players to move their products into the facility. For the Prague nutraceutical business, big orders are under discussion but not yet confirmed; conversion to confirmed orders is expected within a quarter or two. The company has pending approvals for certain products affecting order execution and revenue recognition timing. Discussions for additional projects similar to the HAL venture are ongoing, but details cannot be disclosed currently due to competitive reas

Sanjiv.Parant.Q2 FY25Pharmaceuticals & Biotechnology

Sanjiv.Parant. Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹165P/E: 27.7Market Cap: ₹208 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

Nutraceutical market is constantly growing globally, presenting strong demand growth potential.
Prague JV business expected to stabilize by Q1 FY26, with annual topline of approx. EUR3.5-4 million initially.
Medium to long-term potential for Prague facility estimated at EUR8-10 million annually by FY27, with scope for expansion.
HAL facility peak revenue potential around INR 105-110 crores with 19% EBITDA margin; capacity utilization expected to reach 95-100% within a few months of operation.
Base business sees growth driven by geographic expansion, new product launches (targeting 15-20 launches annually), and increased penetration in existing markets.
Export-driven growth with current export to domestic sales mix approximately 72:28.
Industry challenges like supply chain disruptions and freight costs may impact short-term, but overall outlook remains optimistic.

Margin guidance

Category 3

Nutraceutical market is expected to grow constantly worldwide, supporting uplift in related revenues.
Prague facility (JV) projected to stabilize by Q1 FY26 with an annual revenue estimate of EUR3.5-4 million and EBITDA margins of 25%-30%.
Medium to long term potential from Prague entity estimated at EUR8-10 million annually post-expansion by FY27.
HAL facility expected to reach peak revenue of INR105-110 crores with EBITDA margins around 19%, achieving near full capacity utilization within a few months.
The company targets launching 15-20 new products annually to expand product portfolio and improve margins over time.
Employee costs to increase due to hiring technical expertise for new facilities and projects, linked with growth.
Overall growth driven by product launches, market penetration, and expansion into new geographies.
Management expects to deliver on commitments and grow the company phenomenally over next couple of years if current demand trends and stability continue.

See what Sanjiv.Parant. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript.
The company reported existing debt of INR 5 crores and cash equivalents of INR 5.2 crores as of September 2024.
They have indicated expected capex of around INR 3.5 crores for the base business in FY25 and INR 35-40 crores for the HAL venture in FY25.
The company seems focused on internal capital allocation and managing working capital efficiently to support growth.
No direct commentary on raising additional funds through debt or equity was made during the call.

Order book

Sanjivani Paranteral Limited is currently executing a few small orders for its Prague facility and is in discussions with several big players to move their products into the facility.
For the Prague nutraceutical business, big orders are under discussion but not yet confirmed; conversion to confirmed orders is expected within a quarter or two.
The company has pending approvals for certain products affecting order execution and revenue recognition timing.
Discussions for additional projects similar to the HAL venture are ongoing, but details cannot be disclosed currently due to competitive reasons.
The company expects stabilization of the Prague facility by Q1 next year, with revenue estimated at EUR3.5 to 4 million annually initially, potentially scaling up to EUR8 to 10 million with expansion by FY27.
HAL joint venture projects are on track, with expectations for full production capacity and peak revenues of INR105-110 crores.

See what Sanjiv.Parant. management said on order book — free account, 30 seconds.

Capex plans

Yes

Capex for the base business was INR 1.46 crores in H1 FY25; expected to be around INR 3.5 crores for FY25 and INR 5.5 crores for FY26.
HAL venture (IV business) capex expected to be around INR 35-40 crores for FY25.
New facility in Pune for infusion project is in pipeline and undergoing various approvals; requiring additional capital and technical hires.
Plant upgrades nearly completed at the Bombay facility; Dehradun facility upgrades to begin soon.
Potential future expansions in Prague facility targeting EUR 8-10 million revenue with possibility of adding a bigger facility.
Discussions ongoing for new projects similar to HAL, but details are not disclosed yet due to competitive reasons.

Track Sanjiv.Parant. — get its next earnings analysis in your feed

How does Sanjiv.Parant. rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSanjiv.Parant.

Rev 2Mar 3

See where Sanjiv.Parant. sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Sanjiv.Parant. rank in Pharmaceuticals & Biotechnology?

Compare Sanjiv.Parant. against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Sanjiv.Parant.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →